Publication | Open Access

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

InflammationChronic Inflammatory DiseasesInfliximab DoseImmunologyGastroenterologyClinical GastroenterologyIncrease ClinicalCorticosteroid-free RemissionUlcerative ColitisMedicineInflammatory Disease